Global News and Digital Insights
for the Healthcare Industry

AstraZeneca and Daiichi Sankyo’s drug shows promising results for breast cancer

AstraZeneca and Daiichi Sankyo’s HER2-targeting drug ‘Enhertu’ may be the answer to HER2-low breast cancers.
The study showed results of their drug reducing the risk of cancer or worsening it by killing nearly half of it. Previously, the patients who were considered out of reach for a targeted therapy can now be treated by Enhertu. This FDA-approved drug can also be expanded for other breast cancer patients.

Read More from MedCity News

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn